<DOC>
	<DOCNO>NCT00054730</DOCNO>
	<brief_summary>This study investigate whether CX516 improve attention , memory , language , behavior adult Fragile X Syndrome and/or Autism . CX516 AMPAKINEÂ® compound . AMPAKINE compound enhance synaptic strength . There evidence suggest synapsis brain individual fragile X syndrome immature abnormal . It possible CX516 may partially correct synaptic transmission defect lead improvement cognitive behavioral functioning . There also reason believe change cause CX516 could helpful manage cognitive behavioral symptom patient autistic disorder . Involvement participant last 28 day . Participants give study medication , physical exam , variety cognitive assessment test study potential drug effectiveness improve disease symptom .</brief_summary>
	<brief_title>Effects CX516 Functioning Fragile X Syndrome Autism</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Inclusion criterion : Fragile X group DNAbased diagnosis Fragile X syndrome Autism group Documented diagnosis ADOS ; ADIR ; CARS GARS Both group 1850 year Measured IQ 85 Measured IQ &gt; 20 Mental age &gt; 30 month Stable medication regimen past 8 week Normal hear Vision correct least 20/50 All female childbearing age must negative pregnancy test enrollment Exclusion criterion : Recent history seizure , epilepsy , blackouts Unresolved medical issue impact performance Behavioral dysfunction point subject cooperate test History druginduced neutropenia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Autism</keyword>
</DOC>